Search research articles
Contact Us
Filters
Showing results (71-80 of 80) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 80 results.
Scientific Reports
|
August 10, 2019
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
Annamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
Scientific Reports
|
February 2, 2020
Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
Annamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2015
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial
J Randolph Hecht, Yung-Jue Bang, Shukui K Qin, et al.
JAMA Oncology
|
October 2, 2025
The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials
Alessandro Pastorino, Heshan Liu, Levi Pederson, et al.
Scientific Reports
|
November 6, 2014
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients
Annamaria Ruzzo, Francesco Graziano, Fabio Galli, et al.
Therapeutic Advances in Medical Oncology
|
February 4, 2020
Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trial
Sandro Barni, Gerardo Rosati, Sara Lonardi, et al.
Journal of the National Cancer Institute
|
April 19, 2007
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial
Stefano Cascinu, Roberto Labianca, Carlo Barone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 18, 2017
Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database
Lindsay A Renfro, Richard M Goldberg, Axel Grothey, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 16, 2020
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative
Romain Cohen, Dewi Vernerey, Carine Bellera, et al.
Lancet (London, England)
|
June 18, 2023
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
Arvind Dasari, Sara Lonardi, Rocio Garcia-Carbonero, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 80) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 80 results.
Scientific Reports
|
August 10, 2019
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
Annamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
Scientific Reports
|
February 2, 2020
Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
Annamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2015
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial
J Randolph Hecht, Yung-Jue Bang, Shukui K Qin, et al.
JAMA Oncology
|
October 2, 2025
The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials
Alessandro Pastorino, Heshan Liu, Levi Pederson, et al.
Scientific Reports
|
November 6, 2014
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients
Annamaria Ruzzo, Francesco Graziano, Fabio Galli, et al.
Therapeutic Advances in Medical Oncology
|
February 4, 2020
Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trial
Sandro Barni, Gerardo Rosati, Sara Lonardi, et al.
Journal of the National Cancer Institute
|
April 19, 2007
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial
Stefano Cascinu, Roberto Labianca, Carlo Barone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 18, 2017
Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database
Lindsay A Renfro, Richard M Goldberg, Axel Grothey, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 16, 2020
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative
Romain Cohen, Dewi Vernerey, Carine Bellera, et al.
Lancet (London, England)
|
June 18, 2023
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
Arvind Dasari, Sara Lonardi, Rocio Garcia-Carbonero, et al.
Page
of 8